Perceptive Advisors’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-825,890
| Closed | -$28M | – | 124 |
|
|
2025
Q4 | $28M | Buy |
825,890
+642,000
| +349% | +$19.9M | 0.5% | 50 |
|
|
2025
Q3 | $4.74M | Hold |
183,890
| – | – | 0.14% | 73 |
|
|
2025
Q2 | $1.47M | Sell |
183,890
-368,478
| -67% | -$2.81M | 0.05% | 74 |
|
|
2025
Q1 | $5.39M | Sell |
552,368
-182,632
| -25% | -$1.8M | 0.19% | 65 |
|
|
2024
Q4 | $9.29M | Buy |
+735,000
| New | +$9.34M | 0.26% | 63 |
|
|
2024
Q2 | – | Sell |
-152,934
| Closed | -$11M | – | 125 |
|
|
2024
Q1 | $11M | Sell |
152,934
-114,560
| -43% | -$15.9M | 0.19% | 74 |
|
|
2023
Q4 | $53.2M | Buy |
267,494
+27,412
| +11% | +$3.39M | 1.19% | 25 |
|
|
2023
Q3 | $31.9M | Sell |
240,082
-45,980
| -16% | -$7.51M | 1.06% | 30 |
|
|
2023
Q2 | $42.8M | Sell |
286,062
-389
| -0.1% | -$60.6K | 1.24% | 23 |
|
|
2023
Q1 | $42.1M | Buy |
286,451
+61,582
| +27% | +$12.5M | 1.24% | 23 |
|
|
2022
Q4 | $35.6M | Buy |
224,869
+10,727
| +5% | +$1.72M | 1% | 30 |
|
|
2022
Q3 | $41.2M | Sell |
214,142
-25,082
| -10% | -$4.74M | 1.2% | 27 |
|
|
2022
Q2 | $34.9M | Sell |
239,224
-110,771
| -32% | -$14.8M | 1.09% | 23 |
|
|
2022
Q1 | $61.6M | Sell |
349,995
-15,951
| -4% | -$3.01M | 1.23% | 21 |
|
|
2021
Q4 | $108M | Buy |
365,946
+2,500
| +0.7% | +$668K | 1.66% | 16 |
|
|
2021
Q3 | $90.3M | Buy |
363,446
+53,988
| +17% | +$14.3M | 1.31% | 20 |
|
|
2021
Q2 | $78.7M | Sell |
309,458
-227
| -0.1% | -$42.4K | 1.02% | 28 |
|
|
2021
Q1 | $55M | Buy |
309,685
+112,500
| +57% | +$18.5M | 0.7% | 41 |
|
|
2020
Q4 | $31.2M | Buy |
+197,185
| New | +$42.9M | 0.33% | 62 |
|
Perceptive Advisors's RAPT Position: Q1 2026 in Review
Perceptive Advisors sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 825,890 shares — an estimated $28M sold.
Perceptive Advisors first reported a position in RAPT in Q4 2020 and held it in 19 quarters. The position peaked at $108M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Perceptive Advisors reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Perceptive Advisors sold 825,890 RAPT Therapeutics shares in Q1 2026, an estimated $28M.
- Perceptive Advisors first reported a position in RAPT Therapeutics in Q4 2020 and held it in 19 quarters.
- Perceptive Advisors's RAPT Therapeutics position peaked at $108M in Q4 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.